Levosimendan Kalceks (Levosimendan)

Levosimendan is used in the management of severe cardiac conditions where enhanced contractility and vasodilation are required.

• Acute decompensated heart failure: improves cardiac output and reduces filling pressures.
• Cardiogenic shock: delivers rapid inotropic support while lowering systemic vascular resistance.
• Post‑cardiac surgery low‑output syndrome: assists in stabilising haemodynamics during recovery.

• Levosimendan binds to troponin C, stabilising its calcium‑bound state and thereby sensitising the contractile apparatus to existing calcium. At the same time it opens ATP‑sensitive potassium channels in vascular smooth muscle, causing hyperpolarisation and vasodilation. The combined positive inotropic and vasodilatory actions lower preload and afterload, enhancing overall cardiac performance without increasing intracellular calcium concentrations.

Levosimendan may be associated with several adverse reactions, ranging from frequent to rare but serious.

Common Side Effects

• Headache: mild to moderate intensity.
• Nausea: occasional gastrointestinal upset.
• Hypotension: transient blood pressure reduction.
• Flushing: transient skin warmth.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure requiring intervention.
• Ventricular tachycardia: potentially life‑threatening rhythm disturbance.
• Myocardial ischemia: chest pain due to reduced coronary perfusion.

When using Levosimendan, clinicians should observe several precautionary measures to ensure patient safety.

• Cardiovascular monitoring: continuous ECG and blood pressure assessment during infusion.
• Hypotension risk: avoid rapid bolus in patients with low baseline blood pressure.
• Arrhythmia susceptibility: monitor for new or worsening arrhythmias, especially in ischemic heart disease.
• Renal impairment: adjust infusion rate cautiously as drug metabolites are renally excreted.
• Hepatic dysfunction: use with caution in severe liver disease due to altered metabolism.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with other medications, influencing its efficacy or safety.

Major Interactions (Avoid)

• Nitrates: additive vasodilatory effect may cause severe hypotension.
• Calcium channel blockers (especially dihydropyridines): may potentiate hypotensive response.
• Beta‑blockers: can blunt the desired inotropic effect.

Moderate Interactions (Monitor Closely)

• Diuretics: may exacerbate electrolyte disturbances and affect haemodynamics.
• ACE inhibitors/ARBs: combined vasodilation may increase risk of hypotension.
• Anticoagulants: monitor for bleeding if hypotension leads to organ hypoperfusion.